Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Drug for Use in Cataract Surgery

By Pharmaceutical Processing | December 23, 2004

WASHINGTON, DC (December 23, 2004) – The Food & Drug Administration (FDA) has announced the approval of Vision Blue (trypan blue ophthalmic solution). Vision Blue is the first product approved in the United States for staining the anterior lens capsule during cataract surgery.

According to the FDA, the use of Vision Blue will enhance the ability of ophthalmologists to remove white cataracts, a very advanced mature cataract (typically seen in countries where medical care is not widely available), by allowing the ophthalmologist to see the capsule as it is cut and removed.

Clean cuts in the capsule are known to reduce some of the risks associated with the surgical removal of a cataract, the FDA said. More than 1.4 million people have cataract surgery each year in the United States, although only a small portion of these cataracts are mature white cataracts.

A cataract is a clouding of the eye’s naturally clear lens. Cataract development is a normal process of aging, but cataracts can also develop from eye injuries, certain diseases, such as diabetes, or medications. The lens focuses light rays on the retina – the layer of light-sensing cells lining the back of the eye – to produce a sharp image. When the lens becomes cloudy, light rays cannot pass through it easily, and vision is blurred.

Surgery is the only way to remove a cataract. Selective staining of the anterior lens capsule with Vision Blue makes it easier to visualize, manipulate, and remove the cloudy lens through a surgical incision, the FDA said, adding the safety and effectiveness of Vision Blue has been established in pediatric patients.

No overall differences in safety and effectiveness have been observed between elderly and younger patients, according to the agency. The adverse reactions from the use of Vision Blue are generally self-limited and of short duration. They include discoloration of intraocular lenses and staining of the posterior lens capsule and the vitreous.

Vision Blue is currently marketed in 30 countries. D.O.R.C. International of the Netherlands is the manufacturer.

Related Articles Read More >

Myths about conveyors and measures to make data-driven purchasing decisions
The blueprint for personalized biopharma
Sai Life Sciences opens dedicated veterinary-API unit alongside flagship Bidar site
This is the logo of Johnson & Johnson.
Johnson & Johnson commits $2B investment to North Carolina manufacturing facility
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE